These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37775682)

  • 61. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy.
    Hermansen K; Madsbad S; Perrild H; Kristensen A; Axelsen M
    Diabetes Care; 2001 Feb; 24(2):296-301. PubMed ID: 11213882
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Indirect comparison of once daily insulin detemir and glargine in reducing weight gain and hypoglycaemic episodes when administered in addition to conventional oral anti-diabetic therapy in patients with type-2 diabetes.
    Fakhoury W; Lockhart I; Kotchie RW; Aagren M; LeReun C
    Pharmacology; 2008; 82(2):156-63. PubMed ID: 18679040
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes.
    Valentine WJ; Goodall G; Aagren M; Nielsen S; Palmer AJ; Erny-Albrecht K
    Adv Ther; 2008 Jun; 25(6):567-84. PubMed ID: 18568451
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index.
    Raslová K; Tamer SC; Clauson P; Karl D
    Clin Drug Investig; 2007; 27(4):279-85. PubMed ID: 17358100
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Insulin detemir reduces weight gain as a result of reduced food intake in patients with type 1 diabetes.
    Zachariah S; Sheldon B; Shojaee-Moradie F; Jackson NC; Backhouse K; Johnsen S; Jones RH; Umpleby AM; Russell-Jones DL
    Diabetes Care; 2011 Jul; 34(7):1487-91. PubMed ID: 21593292
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study.
    Meneghini LF; Rosenberg KH; Koenen C; Merilainen MJ; Lüddeke HJ
    Diabetes Obes Metab; 2007 May; 9(3):418-27. PubMed ID: 17391170
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin.
    Pieber TR; Draeger E; Kristensen A; Grill V
    Diabet Med; 2005 Jul; 22(7):850-7. PubMed ID: 15975098
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Differences between long-acting insulins for the treatment of type 2 diabetes.
    Jensen MG; Hansen M; Brock B; Rungby J
    Expert Opin Pharmacother; 2010 Aug; 11(12):2027-35. PubMed ID: 20642370
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Decrease in clinical hypoglycemia in young children with type 1 diabetes treated with free-mixed aspart and detemir insulin: an open labeled randomized trial.
    Petit-Bibal C; Rothenbuhler A; Lucchini P; Aboumrad B; Castell AL; Le Fur S; Bougnères P
    Pediatr Diabetes; 2015 Aug; 16(5):345-53. PubMed ID: 24888575
    [TBL] [Abstract][Full Text] [Related]  

  • 70. No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis.
    Dejgaard A; Lynggaard H; Råstam J; Krogsgaard Thomsen M
    Diabetologia; 2009 Dec; 52(12):2507-12. PubMed ID: 19838665
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comparative effectiveness and safety of different basal insulins in a real-world setting.
    Ji L; Zhang P; Zhu D; Lu J; Guo X; Wu Y; Li X; Ji J; Jia W; Yang W; Zou D; Zhou Z; Gao Y; Garg SK; Pan C; Weng J; Paul SK;
    Diabetes Obes Metab; 2017 Aug; 19(8):1116-1126. PubMed ID: 28230322
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus.
    Mullins P; Sharplin P; Yki-Jarvinen H; Riddle MC; Haring HU
    Clin Ther; 2007 Aug; 29(8):1607-19. PubMed ID: 17919543
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis.
    Monami M; Marchionni N; Mannucci E
    Diabetes Obes Metab; 2009 Apr; 11(4):372-8. PubMed ID: 19267715
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes.
    Kølendorf K; Ross GP; Pavlic-Renar I; Perriello G; Philotheou A; Jendle J; Gall MA; Heller SR
    Diabet Med; 2006 Jul; 23(7):729-35. PubMed ID: 16842476
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden.
    Smith-Palmer J; Fajardo-Montañana C; Pollock RF; Ericsson A; Valentine WJ
    J Med Econ; 2012; 15(5):977-86. PubMed ID: 22563742
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P; Cooper J; Bregnhøj J; Pedersen CB
    Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Comparison between the effect of regular human insulin and NPH with novo-rapid and levemir insulin in glycemic control in gestational diabetes.
    Amini FG; Nia AF; Sharbafi MH; Khandari A; Gargari SS
    Hum Antibodies; 2019; 27(4):285-289. PubMed ID: 31156155
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Switching from NPH insulin to once-daily insulin detemir in basal-bolus-treated patients with diabetes mellitus: data from the European cohort of the PREDICTIVE study.
    Sreenan S; Virkamäki A; Zhang K; Hansen JB;
    Int J Clin Pract; 2008 Dec; 62(12):1971-80. PubMed ID: 19166444
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Short-term effects of NPH insulin, insulin detemir, and insulin glargine on the GH-IGF1-IGFBP axis in patients with type 1 diabetes.
    Ma Z; Christiansen JS; Laursen T; Lauritzen T; Frystyk J
    Eur J Endocrinol; 2014 Oct; 171(4):471-9. PubMed ID: 25005937
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A retrospective study comparing neutral protamine hagedorn insulin with glargine as basal therapy in prednisone-associated diabetes mellitus in hospitalized patients.
    Dhital SM; Shenker Y; Meredith M; Davis DB
    Endocr Pract; 2012; 18(5):712-9. PubMed ID: 22784834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.